These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 11987442)

  • 21. Model to assess the cost-effectiveness of new treatments for depression.
    Sobocki P; Ekman M; Agren H; Jönsson B; Rehnberg C
    Int J Technol Assess Health Care; 2006; 22(4):469-77. PubMed ID: 16984680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness analysis of screening for lung cancer with low dose spiral CT (computed tomography) in the Australian setting.
    Manser R; Dalton A; Carter R; Byrnes G; Elwood M; Campbell DA
    Lung Cancer; 2005 May; 48(2):171-85. PubMed ID: 15829317
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Hip protectors: what is their role in the prevention of femoral fractures?].
    Ruggieri G; Bosshard W; Büla C
    Rev Med Suisse Romande; 2000 Nov; 120(11):887-92. PubMed ID: 11140307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does a hip protector reduce the risk of hip fracture in frail elderly patients?
    Markova T; Schwartz K
    J Fam Pract; 2001 Mar; 50(3):259. PubMed ID: 11252220
    [No Abstract]   [Full Text] [Related]  

  • 26. Evaluation of the cost-effectiveness in the United States of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults.
    Pellissier JM; Brisson M; Levin MJ
    Vaccine; 2007 Nov; 25(49):8326-37. PubMed ID: 17980938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of hip protectors in institutional dwelling elderly.
    Waldegger L; Cranney A; Man-Son-Hing M; Coyle D
    Osteoporos Int; 2003 May; 14(3):243-50. PubMed ID: 12730792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Prevention of fractures and the use of hip protectors in the elderly: it is still too early for recommendations].
    Emmelot-Vonk MH; Verhaar HJ
    Ned Tijdschr Geneeskd; 2005 May; 149(19):1038-42. PubMed ID: 15909392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost effectiveness and cost utility of risedronate for osteoporosis treatment and fracture prevention in women: a Swiss perspective.
    Wasserfallen JB; Krieg MA; Greiner RA; Lamy O
    J Med Econ; 2008; 11(3):499-523. PubMed ID: 19450101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost effectiveness of community-based physical activity interventions.
    Roux L; Pratt M; Tengs TO; Yore MM; Yanagawa TL; Van Den Bos J; Rutt C; Brownson RC; Powell KE; Heath G; Kohl HW; Teutsch S; Cawley J; Lee IM; West L; Buchner DM
    Am J Prev Med; 2008 Dec; 35(6):578-88. PubMed ID: 19000846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are hip protectors cost effective?
    Kumar BA; Parker MJ
    Injury; 2000 Nov; 31(9):693-5. PubMed ID: 11084156
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of hip protectors in frail institutionalized elderly.
    van Schoor NM; de Bruyne MC; van der Roer N; Lommerse E; van Tulder MW; Bouter LM; Lips P
    Osteoporos Int; 2004 Dec; 15(12):964-9. PubMed ID: 15103454
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost-effectiveness of fracture prevention treatments in the elderly.
    Fleurence RL
    Int J Technol Assess Health Care; 2004; 20(2):184-91. PubMed ID: 15209178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Does fall-related self-efficacy in hip-protector users affect quality of life and physical activity in nursing homes in Japan?
    Kato C; Ida K; Hoshiyama M; Harada A
    J Am Geriatr Soc; 2010 Sep; 58(9):1810-2. PubMed ID: 20863350
    [No Abstract]   [Full Text] [Related]  

  • 35. Factors influencing hip protector use among community-dwelling older adults.
    Blalock SJ; Demby KB; McCulloch KL; Stevens JA
    Inj Prev; 2010 Aug; 16(4):235-9. PubMed ID: 20587816
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Cost-effectiveness of hip fracture in Japan].
    Ota T; Harada A; Tokuda H
    Nihon Ronen Igakkai Zasshi; 2002 Sep; 39(5):483-8. PubMed ID: 12404738
    [No Abstract]   [Full Text] [Related]  

  • 37. Cost effectiveness of external hip protectors in the hospital setting: a modeling study.
    Stollenwerk B; Waldeyer R; Klein-Meding C; Müller D; Stock S
    Nurs Econ; 2014; 32(2):89-98. PubMed ID: 24834633
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wearing hip protectors does not reduce health-related quality of life in older people.
    Schaafsma FG; Kurrle SE; Quine S; Lockwood K; Cameron ID
    Age Ageing; 2012 Jan; 41(1):121-5. PubMed ID: 21896557
    [No Abstract]   [Full Text] [Related]  

  • 39. Hip protectors need an evidence base.
    Kannus P; Parkkari J; Khan K
    Lancet; 2003 Oct; 362(9391):1168-9. PubMed ID: 14568734
    [No Abstract]   [Full Text] [Related]  

  • 40. Hip protectors are cost-effective in the prevention of hip fractures in patients with high fracture risk.
    de Bot RTAL; Veldman HD; Witlox AM; van Rhijn LW; Hiligsmann M
    Osteoporos Int; 2020 Jul; 31(7):1217-1229. PubMed ID: 32040600
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.